

EACR

European Association
for Cancer Research

CONFERENCES

www.eacr.org

EACR Conference

Defence is the Best Attack

Immuno-oncology Breakthroughs

09 - 11 May 2023 | Barcelona, Spain

Scientific Programme Committee

Joan Seoane (Chair),

Lillian Siu, Alena Gros,

Ignacio Melero, Yardená Samuels

Scan the QR code to access online
conference resources, including speaker
and poster abstracts

eacr.org/conference/immunooncology2023



Save the date

eacr.org/conference



Don't forget the next EACR Congress... eacr2023.org



12-15 June 2023
Torino, Italy

Innovative Cancer Science

European Association for Cancer Research

**EARLY CAREER
RESEARCHERS' CONFERENCE**

VIRTUAL EVENT
27 - 28 June 2023

EACR Conference

GOODBYE FLAT BIOLOGY

Next Generation Cancer Models

Berlin, Germany

10 - 12 October 2023

EACR-AstraZeneca Conference

CANCER EPIGENETICS

Virtual event

05 - 06 December 2023

EACR
European Association
for Cancer Research

AACR
American Association
for Cancer Research

EACR-AACR Basic & Translational Research Conference
Dublin, Ireland | 27 - 29 February 2024

HOW TO BRING BASIC SCIENCE TO THE CLINIC

In partnership
with IACR

IACR
IRISH ASSOCIATION FOR CANCER RESEARCH

EACR Conference

Defence is the Best Attack 2023

#eacrImmunoOncology | WiFi: Convidats_Pedrera | Password: pedrer@12k17

Day 1 | Tuesday 09 May

From 11:30

REGISTRATION

Posters 1-46
can be put up

12:00 – 13:00

 WELCOME LUNCH

A chance to meet fellow attendees and enjoy a light buffet lunch

13:00 – 13:10

CONFERENCE WELCOME
Scientific Programme Committee

13:10 – 13:40

Q&A: 13:40 – 13:55

SESSION 1 Chair: Joan Seoane

OPENING KEYNOTE LECTURE

Alberto Mantovani Humanitas University, Italy

"Innate immunity, inflammation, and cancer from bench to bedside"

13:55 – 14:15

Q&A: 14:15 – 14:25

Jennifer Guerriero Brigham and Women's Hospital/
Harvard Medical School, USA

"Targeting novel populations of macrophages for anti-cancer therapy"

14:25 – 14:35

Q&A: 14:35 – 14:40

Krijn Dijkstra Antoni van Leeuwenhoek - Netherlands
Cancer Institute, Netherlands

Proffered Paper 1: "Patient-derived co-cultures of TRACERx lung cancer organoids and autologous T-cells reveal heterogeneity in immune evasion between cancer subclones"

14:40 – 14:50

EXHIBITOR INTRODUCTIONS

60-second intro pitches by each company

14:50 – 15:20

 COFFEE BREAK & EXHIBITION

15:20 – 15:40

Q&A: 15:40 – 15:50

SESSION 2 Chair: Ignacio Melero

Joan Seoane Vall d'Hebron Institute of Oncology, Spain

"Impact of the tumor microenvironment on immunotherapy"

15:50 – 16:10
Q&A: 16:10 – 16:20

Sonia Guedan Hospital Clinic de Barcelona, Spain
"CAR-T cells for the treatment of solid tumors"

16:20 – 16:30

POSTER SPOTLIGHTS

Posters 1, 20, & 35 will be presented in short 3-minute 'flash talks'

16:30 – 16:50
Q&A: 16:50 – 17:00

Alena Gros Vall d'Hebron Institute of Oncology, Spain
"Towards tailored antitumor T-cell therapies"

17:00 – 17:20
Q&A: 17:20 – 17:30

Gabriel Rabinovich The Institute of Biology and Experimental Medicine/CONICET, Argentina
"The emerging role of glyco-checkpoints in cancer: the 'sweet' side of immunotherapy"

17:30 – 18:15

 **WELCOME RECEPTION** *with drinks and a light buffet*

18:15 – 19:45

POSTER DISCUSSION SESSION 1

Presenters of posters 1 - 46 should stand by their boards

Day 2 | Wednesday 10 May

08:15 – 08:45

 **MORNING COFFEE & POSTER VIEWING**

08:45 – 09:00

SESSION 3 Chair: Yardena Samuels

INDUSTRY SPOTLIGHT - AGILENT TECHNOLOGIES

Miriam Contreras Mostazo Agilent Technologies
"How to assess T-cell metabolic profile and further develop effective T-cell therapies using Seahorse Analyzer"

09:00 – 09:20
Q&A: 09:20 – 09:30

Ignacio Melero Clinica Universidad de Navarra, Spain
"Tumor IL-8, NETs, and the wrong type of tumor inflammation"

09:30 – 09:40
Q&A: 09:40 – 09:45

Jörg Wischhusen University Hospital Würzburg, Germany
Proffered Paper 2: "Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment"

09:45 – 10:05
Q&A: 10:05 – 10:15

Keren Yizhak Technion - Israel Institute of Technology, Israel
"Estimating tumor mutational burden from 'tumor-only' RNA-sequencing data"

10:15 – 10:35
Q&A: 10:35 – 10:45

Mustafa Diken TRON/Biontech, Germany
"The evolution of mRNA-vaccines against cancer"

10:45 – 11:15

 **COFFEE BREAK & EXHIBITION**

Take down
posters 1-46

Posters 47-92
can be put up

11:15 – 11:35

Q&A: 11:35 – 11:45

THE EMBO KEYNOTE LECTURE

Yardena Samuels Weizmann Institute of Science, Israel
"Revisiting the Neoantigen Approach for Cancer Immunotherapy"

11:45 – 11:55

Q&A: 11:55 – 12:00

Macarena Román Vall d'Hebron Institute of Oncology, Spain
Proffered Paper 3: "p95HER2 CAR Ts secreting HER2 BITes are a safe and effective immunotherapeutic strategy against HER2-positive tumors"

12:00 – 12:10

POSTER SPOTLIGHTS

Posters 50, 70, & 90 will be presented in short 3-minute 'flash talks'

12:10 – 12:40

INDUSTRY SYMPOSIUM - BIO-RAD LABORATORIES

Andres Ramirez Venegas BIO-RAD Laboratories
"Overcoming Bottlenecks in Research & Discovery with High-Throughput Flow Cytometry"

12:40 – 13:20

LUNCH & EXHIBITION

13:20 – 14:50

POSTER DISCUSSION SESSION 2

Presenters of posters 47 - 92 should stand by their boards

SESSION 4 Chair: Lillian Siu

14:50 – 15:05

INDUSTRY SPOTLIGHT - LYNXCARE

Dr Annelies Verbiest Antwerp University Hospital, Belgium
"Defense through Insights: Using AI to Unlock Real-World Evidence in Immunotherapy"

15:05 – 15:35

Q&A: 15:35 – 15:50

KEYNOTE LECTURE

Tyler Jacks Massachusetts Institute of Technology, USA
"Genetic engineering meets tumor immunology: Lessons from mouse models of cancer"

15:50 – 16:10

Q&A: 16:10 – 16:20

Lillian Siu University of Toronto, Canada
"Circulating DNA Applications in the Immuno-Oncology Era"

16:20 – 16:30

Q&A: 16:30 – 16:35

Marni Nishimoto Johns Hopkins University, USA
Proffered Paper 4: "Transcriptional Programs of Tumor Specific CD4⁺ T Cells in NSCLC"

16:35 – 16:45

Q&A: 16:45 – 16:50

Giuseppina Arbore Ospedale San Raffaele, Italy
Proffered Paper 5: "Immune determinants of response to neoadjuvant chemotherapy in esophageal adenocarcinoma"

16:50 – 17:20

COFFEE BREAK & EXHIBITION

17:20 – 17:40
Q&A: 17:40 – 17:50

Pablo Umaña Roche, Switzerland

"Enhancing endogenous and synthetic immunity with engineered antibody-fusion proteins for cancer immunotherapy"

17:50 – 18:10
Q&A: 18:10 – 18:20

Sergio Quezada Cancer Research UK, UK

"Regulatory T-cells as Determinants of Adaptive and Innate Immune Function in Brain Tumours"

18:20 – 18:50

MEET THE SCIENTIFIC PROGRAMME COMMITTEE
Joan Seoane, Lillian Siu, Alena Gros, Ignacio Melero, & Yarden Samuels

Our esteemed Scientific Programme Committee will come together to each provide insight into their personal and professional experiences of their routes to scientific leadership

20:00

 **OPTIONAL CONFERENCE DINNER** Hotel Casa Fuster
For those who have purchased tickets

Day 3 | Thursday 11 May

08:30 – 09:00

 **MORNING COFFEE & POSTER VIEWING**

09:00 – 09:20
Q&A: 09:20 – 09:30

SESSION 5 Chair: Alena Gros

Andrea Ablasser EPFL, Switzerland

"Sensing DNA as a danger signal through the cGAS-STING pathway"

09:30 – 09:50
Q&A: 09:50 – 10:00

Marisol Soengas CNIO, Spain

"Dissecting and targeting immune suppressive signals in the melanoma microenvironment"

10:00 – 10:10
Q&A: 10:10 – 10:15

Eudald Felip Institut Catala Oncologia, Spain

Proffered Paper 6: "Enhanced tumor immunity determines CDK4/6 inhibitor efficacy in advanced breast cancer (BC)"

10:15 – 10:45

 **COFFEE BREAK & EXHIBITION**

10:45 – 11:15

Susan Galbraith (virtual presentation) AstraZeneca, UK

"Exploring the next wave of immuno-oncology therapies"

11:15 – 11:45
Q&A: 11:45 – 12:00

CLOSING KEYNOTE LECTURE

Josep Tabernero Vall d'Hebron Institute of Oncology, Spain

Talk title not available at time of printing

12:00

SUMMARY, AWARDS & DEPART

Travel Grants

More information about EACR grants: eacr.org/travel-grant

EACR-Worldwide Cancer Research Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Travel Grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

Cléa Dziagwa BELGIUM

Abolaji Olagunju BRAZIL

Alberto Traverso THE NETHERLANDS

Didem Karakas Zeybek TURKEY



**worldwide
cancer
research**

A number of Travel Grants have also been awarded by the **European Federation of Immunological Societies' (EFIS) European Journal of Immunology (EJI)** to help early-career researchers who need financial assistance to attend the conference and present their work as an oral or poster presentation. Each EFIS-EJI Travel Grant includes a free registration and funds to support travel and accommodation costs. Congratulations to the recipients:


Annica Barizza ITALY

Xiaokang Li SWITZERLAND

Flor Navarro SPAIN



Exhibition Floor Plan



Keynote lecture sponsor:



AstraZeneca has provided a sponsorship grant towards this independent Programme

Exhibitors

1. SB-PEPTIDE
2. Cell Signaling Technology
3. LynxCare
4. Agilent Technologies
5. Bio-Rad Laboratories
6. VectorBuilder

Meet the Exhibitors

SB-PEPTIDE Stand: 1

Website: www.sbpeptide.com

Represented at the conference by:

Marine Hoscar



Cell Signaling Technology Stand: 2

Website: www.cellsignal.com



LynxCare Stand: 3

Website: www.lynx.care

Represented at the conference by:

Annelies Verbiest, Clara Oeste, Georges De Feu, Carlos Bringas

Spotlight: Wednesday 10 May | 14:50 - 15:10

Dr Annelies Verbiest: "Defence through Insights: Using AI to Unlock Real-World Evidence in Immunotherapy"



Agilent Technologies Stand: 4

Website: www.agilent.com

Represented at the conference by:

Miriam Contreras Mostazo, Carles Ramos Solé, Franck Teyssier

Spotlight: Wednesday 10 May | 08:45 - 09:00

Miriam Contreras Mostazo: "How to assess T-cell metabolic profile and further develop effective T-cell therapies by using Seahorse Analyzer"



Bio-Rad Laboratories Stand: 5

Website: www.bio-rad.com

Represented at the conference by:

Marc Martin, JuanCarlos Fernandez, Andres Ramirez Venegas

Symposium: Wednesday 10 May | 12:10 - 12:40

Andres Ramirez Venegas: "Overcoming Bottlenecks in Research & Discovery with High-Throughput Flow Cytometry"



VectorBuilder Stand: 6

Website: www.vectorbuilder.com

Represented at the conference by: Maria Blasco



Poster Index

View abstracts when logged-in at eacr.org/conference/immunooncology2023

- 1 **[POSTER SPOTLIGHT]** The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2
[Presented by Jose Alberto Lopez-Dominguez, IRB Barcelona, SPAIN](#)
- 2 Understanding the role of VISTA in regulating T cell function and the therapeutic potential of blocking VISTA in Triple Negative Breast Cancer
[Presented by Maidinaimu Abudula, University of Liverpool, UK](#)
- 3 Hsp70-Bag3 module regulates macrophage motility and tumor infiltration via transcription factor LITAF and CSF1 [Presented by Elena Avinery, Ariel university, ISRAEL](#)
- 4 Short alanine-based spacers included in poly-neoantigen vaccines improve peptide processing and presentation to CD8⁺ T cells [Presented by Ana Barajas, IrsiCaixa AIDS Research Institute, Badalona & Central University of Catalonia, Vic, SPAIN](#)
- 5 Elucidating the Mechanism of Action of IL5 as a Promoter of IFN Expression by Mast Cells in the Tumor Microenvironment [Presented by Jasmine Barra, Dalhousie University, Halifax/Nova Scotia, CANADA](#)
- 6 HPV-induced LIF expression promotes immune evasion in cervical cancer [Presented by Ester Bonfill, VHIO, Barcelona, SPAIN](#)
- 7 NZ-TLR9 shows antitumoral activity against both treated and untreated tumors in various rodent models and is characterised by a promising safety and PK/PD profile [Presented by Erwin Brenndörfer, LIDDS AB, Uppsala, SWEDEN](#)
- 8 Targeted nanotoxin for the selective depletion of CXCR4⁺ cancer cells and immune cell recruitment in a colorectal cancer mouse model [Presented by Luis Miguel Carrasco Díaz, Institut d'Investigació Biomèdica Sant Pau & Josep Carreras Leukaemia Research Institute, Barcelona, SPAIN](#)
- 9 MYC inhibition by Omomyc induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing drug activity [Presented by Silvia Casacuberta Serra, Peptomyc S.L., Barcelona, SPAIN](#)
- 10 Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists and TGF- antagonists [Presented by Assunta Cirella, Cima Universidad de Navarra & IDISNA, Pamplona, SPAIN](#)
- 11 An engineered 3D model to probe the interactions between macrophages and tumor cells in the graded hypoxic environment of pancreatic cancer [Presented by Ileana Co, University of Toronto, CANADA](#)

- 12 Dual VEGFA/BRAF targeting synergizes with immunotherapy through GM-CSF-mediated M1-macrophages infiltration [Presented by Valentina Comunanza, University of Torino & IRCCS, Candiolo, ITALY](#)
- 13 Evaluating the applicability of CX3CR1 antagonism to promote NK cell migration towards tumour in obesity-associated cancer [Presented by Melissa Conroy, Trinity College Dublin, IRELAND](#)
- 14 Effects of the TGFRI inhibitor Galunisertib on pancreatic ductal adenocarcinoma tumor micro and macroenvironment [Presented by Martina Cucchiara, University of Insubria, Varese, ITALY](#)
- 15 Proteasome activation prevents T cell exhaustion and promotes anti-tumor immunity [Presented by Ander de Blas Martin, CIC bioGUNE, Derio, SPAIN](#)
- 16 Sorafenib and Lenvatinib induce vascular responses in patient derived HCC on-Chip models [Presented by Luuk de Haan, MIMETAS BV, Oegstgeest, NETHERLANDS](#)
- 17 Unravelling tumor-intrinsic resistance mechanisms to T-cell mediated cytotoxicity in pancreatic cancers [Presented by Judit Gomez, VHIO, Barcelona, SPAIN](#)
- 18 Impact of KEOPS-complex tRNA modification on antitumor immune response in melanoma [Presented by Cléa Dziagwa, University of Liège, BELGIUM](#)
- 19 Siglec-15 binds to glycosylated CD11b expressed on activated T cells [Presented by Leire Egia, CICbioGUNE, Derio, SPAIN](#)
- 20 **[POSTER SPOTLIGHT]** The association of Parvimonas micra and Fusobacterium nucleatum to the tumour immune response in colorectal cancer [Presented by Thyra Löwenmark, Department of Medical Biosciences, Pathology, Umeå, SWEDEN](#)
- 21 MHC class I and II deficiency in humanized murine models prevents xenograft-versus-host disease (xGVHD) allowing the characterization of antitumor immune responses [Presented by Iñaki Eguren, CIMA Universidad de Navarra, Pamplona, SPAIN](#)
- 22 Investigating how the metastatic niche impairs NK cell cytotoxicity in early lung metastasis from breast cancer [Presented by Christos Ermogenous, Barts Cancer Institute, London, UK](#)
- 23 Using live tumour slices to assess CAR-T cell efficacy in pancreatic cancer [Presented by Alice Evans, University of Oxford, UK](#)
- 24 Efficacy of HuR small molecule inhibitors in breast cancer models [Presented by Elisa Facen, University of Trento, ITALY](#)

25 Ribosomal protein LP1 is required for efficient antigen presentation in melanoma cells [Presented by William Faller, NKI, Amsterdam, NETHERLANDS](#)

26 PREDIG: An explainable ML-based predictor of T-cell epitope immunogenicity [Presented by Roc Farriol Duran, Barcelona Supercomputing Center \(BSC\), SPAIN](#)

27 Derazantinib improves tumor immunity in an ex-vivo model of non-small cell lung cancer based on thin sections of patient-derived tumor biopsies [Presented by Patricia Fernandez Nogueira, University of Barcelona, SPAIN](#)

28 Stealth zwitterionic graft mRNA for anti-tumoral application and controlled inflammatory response [Presented by Cristina Fornaguera Puigvert, Universitat Ramon Llull, Barcelona, SPAIN](#)

29 Characterization of tumor-infiltrating (TINKs) and tumor-associated (TANKs) Natural Killer cells in patients with prostate cancer [Presented by Matteo Gallazzi, IRCCS MultiMedica, Milan, ITALY](#)

30 Preclinical and patient transcriptomics RNA-seq highlight the impact of TNF blockade on the inflammatory status of melanoma tumors [Presented by Matthieu Genais, Université Toulouse III & Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, FRANCE](#)

31 The Role of Dual-Specificity Phosphatase 10 (DUSP10) in Hepatocellular Carcinoma (HCC) [Presented by Jian Yi Gerald Goie, National University of Singapore, SINGAPORE](#)

32 Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition [Presented by Íñigo González Larreategui, VHIO, Barcelona, SPAIN](#)

33 Neoadjuvant treatment of a localized breast cancer recurrence by oncolytic viruses – A case study [Presented by Beata Halassy, University of Zagreb & Center of Excellence for Virus Immunology and Vaccines, Zagreb, CROATIA](#)

34 PDTTCs (patient-derived tumor tissue cultures) as new platform for assessing immunotherapy efficacy in glioblastoma [Presented by Raffaella Iurlaro, VHIO, Barcelona, SPAIN](#)

35 **[POSTER SPOTLIGHT]** Introduction of an AI companion in clinical practice for the prediction of immunotherapy side effects in metastatic lung cancer patients [Presented by Alberto Traverso, Maastricht University Medical Center, NETHERLANDS](#)

36 Quantitative proteomic landscape of IFN associated immune escape mechanisms [Presented by Agnete Jensen, University of Copenhagen, DENMARK](#)

37 Generation of zebrafish models of acute myeloid leukemia for high throughput chemical screening [Presented by Alba Jiménez Blaya, Universidad de Murcia & IMIB-Pascual Parrilla, Murcia, SPAIN](#)

38 Targeting pancreatic cancer stroma makes pancreatic cancer spheroids more vulnerable to natural killer cell-mediated cytotoxicity [Presented by Didem Karakas-Zeybek, Istinye University, Istanbul, TURKEY](#)

39 Profiling the Non-Small Cell Lung Cancer (NSCLC) microenvironment across disease stages [Presented by Marcelo Hurtado, Université Toulouse III, FRANCE](#)

40 Electrochemotherapy as in situ vaccine and peritumoral gene electrotransfer of IL-12 [Presented by Simona Kranjc Brezar, Institute of Oncology Ljubljana & University of Ljubljana, SLOVENIA](#)

41 Novel markers of CD19 CAR-T therapy-resistant malignancies [Presented by Marta Krawczyk, Medical University of Warsaw & Polish Academy of Sciences, Warsaw, POLAND](#)

42 CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies [Presented by Aleksandra Kusowska, Medical University of Warsaw, POLAND](#)

43 Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma [Presented by Julia Lehmann, University of Zurich, SWITZERLAND](#)

44 A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics [Presented by Xiaokang Li, University of Lausanne & CHUV, Lausanne, SWITZERLAND](#)

45 Activated/fibrotic TAF-mediated immunosuppression in NSCLC and its effect on macrophage differentiation [Presented by Alejandro Llorente Alvarez, University of Barcelona & IBEC, Barcelona, SPAIN](#)

46 Cancer Cell Plasticity Defines Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma [Presented by Laura Lorenzo Sanz, IDIBELL, L'Hospitalet de Llobregat, SPAIN](#)

47 Different immunomodulatory functions of PARP-1 and PARP-2 are contributing to the opposite effect of these two proteins in B cell lymphoma [Presented by Nura Lutfi Royo, Hospital del Mar Medical Research Institute, Barcelona, SPAIN](#)

48 Novel compounds for immune checkpoint modulation in dendritic cells towards improved cancer immunotherapies [Presented by Vanessa Luz, Universidade NOVA de Lisboa, Almada, PORTUGAL](#)

49 Deconvolution-based estimation of immune cell fractions in blood for immunotherapy response prediction in non-small cell lung cancer patients. Presented by Alvaro Marcos Rubio, VIB & Ghent University, Ghent, BELGIUM

50 **[POSTER SPOTLIGHT]** Triple combination of anti-CTLA-4, anti-PD-1 and anti-TNF in mouse melanoma models and advanced melanoma patients Presented by Bruno Ségui, Université Toulouse & Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, FRANCE

51 Selective PARP-2 targeted therapy as a new strategy in pancreatic cancer Presented by Neus Martinez, Unidad Asociada IIBB-CSIC, Barcelona, SPAIN

52 Multiparametric functional immune analysis of liquid biopsy identifies TIGIT, TIM3 and TNF as colon cancer diagnostic markers Presented by Pablo Mata Martínez, La Paz University Hospital, Madrid, SPAIN

53 Upregulation of pattern recognition receptors after gene electrotransfer of plasmid encoding IL-12 Presented by Ajda Medved, Institute of Oncology Ljubljana & University of Ljubljana, SLOVENIA

54 Single-Cell Mapping Identifies AXL as a Driver of Local Immune Suppression and an Actionable Tumor-Extrinsic Target in Brain Metastasis Presented by Hind Medyouf, Georg-Speyer-Haus & Goethe University, Frankfurt am Main, GERMANY

55 Artificial extracellular matrices based on synthetic hydrogels for T cell culture Presented by Francesca Merlina, ICMAB-CSIC, Barcelona, SPAIN

56 Viral Infection and RIG-I Stimulation Enhance NK Cell Activation Towards Target Cells Presented by Adham Mohamed, University Hospital Bonn, GERMANY & University of Melbourne, AUSTRALIA

57 A combinatorial therapy for bladder cancer: epigenetic inhibitor and CAR-NK cells Presented by Lucia Morales Rodriguez, CIEMAT & Hospital Universitario "12 de Octubre", Madrid, SPAIN

58 Immune and stromal crosstalk in the early stages of ovarian cancer metastasis: a role for type-2 innate lymphoid cells? Presented by Julia Moreno-Vicente, Cancer Research UK Cambridge Institute, UK

59 Systemic BCG administration in mice stimulates antitumor immunity in the lung and overcomes resistance to immune checkpoint blockade Presented by Eduardo Moreo, University of Zaragoza & CIBERES, Madrid, SPAIN

60 Genomic instability and DNA damage regulate STING activation through characteristic cytosolic DNA structures in colorectal cancer Presented by Shayla Mosley, University of Alberta, Edmonton, CANADA

61 Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy [Presented by Flor Navarro, University of Navarra, IdiSNA, CIBERONC, Pamplona, SPAIN](#)

62 Modulation of tumour microenvironment by targeting epigenetic mechanisms in bladder cancer [Presented by Sandra P. Nunes, Porto.CCC, PORTUGAL & CIEMAT, Madrid, SPAIN](#)

63 CASPASE 1 but not GSDMD contributes to recombinant listeria-driven antitumor immune responses [Presented by Abolaji Olagunju, University of Sao Paulo, BRAZIL](#)

64 Lipid-loaded macrophages sustain melanoma progression [Presented by Marta Pandini, Humanitas University & IRCCS, Milano, ITALY](#)

65 Nanoparticles for CAR T cell manufacturing: a potential gene delivery platform [Presented by Inês Pinto, University of Coimbra & University of Aveiro, PORTUGAL](#)

66 Quantification of brain metastasis-infiltrating T-cells in blood using ultra-deep single-cell T-cell repertoire sequencing [Presented by Ester Planas-Rigol, VHIO, Barcelona, SPAIN](#)

67 Functional precision profiling deciphers patient-specific signaling rewiring in colorectal cancer [Presented by Christina Plattner, Medical University of Innsbruck, AUSTRIA](#)

68 The alarmin-like RNASET2 molecule exerts cell-autonomous and non-cell autonomous activities in prostate cancer models. [Presented by Rossella Roncoroni, University of Insubria, Varese, ITALY](#)

69 Preclinical investigation of combined immune checkpoint blockade and anti-angiogenic therapy in malignant pleural mesothelioma [Presented by Sophie Rovers, University of Antwerp, Wilrijk, BELGIUM](#)

70 **[POSTER SPOTLIGHT]** CD300e shapes the function of tumor-associated macrophages in colorectal cancer [Presented by Annica Barizza, University of Padova, Padova, ITALY](#)

71 Effect of Autophagy inhibition on predictive biomarkers of immunotherapy in Colorectal Cancer cells of different mismatch repair status [Presented by Maha Saber-Ayad, University of Sharjah & Sharjah Institute for Medical Research, UNITED ARAB EMIRATES](#)

72 Revoking immune-suppression in a mouse model of brain metastases enhances efficacy of immune-targeted therapy [Presented by Anna Salamero Boix, Georg-Speyer-Haus & Goethe University, Frankfurt am Main, GERMANY](#)

73 FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer [Presented by Alan Serrels, University of Edinburgh, UK](#)

74 Transforming Immune System Cells: A Novel Approach to Fight Triple-Negative Breast Cancer Using Ambrosia confertiflora Extract [Presented by Tzipora Shmueli, Ariel University, ISRAEL](#)

75 Cytokine and chemokine gene expression signature as a predictive tool to select between target therapy or immunotherapy in BRAF-mutated cutaneous melanoma patients [Presented by Carme Solé Blanch, IGTP, Badalona, SPAIN](#)

76 A 3D lung tumor on a chip model to study the modulation of T cell infiltration under flow conditions in a high-throughput microfluidic culture system [Presented by Johnny Suijker, Mimetas BV, Oegstgeest, NETHERLANDS](#)

77 SPARC repression of PD-1 on Treg drives immune suppression in high-grade breast cancer [Presented by Giovanna Talarico, European Institute of Oncology, Milano, ITALY](#)

78 Inhaled lung cancer nano-immunotherapies based on gene-loaded pBAE nanoparticles: in deep studies of their diffusion capacity through lung mucosa [Presented by Antoni Torres, Universitat Ramón Llull \(URL\), Barcelona, SPAIN](#)

79 Unleashing natural killer (NK) cells to promote anti-leukemic immunity [Presented by Ioanna Tsoukala, Georg-Speyer-Haus, Frankfurt am Main, GERMANY](#)

80 Transferring multivariate models of response to immune checkpoint inhibitors to varied clinical settings [Presented by Joseph Usset, IRB Barcelona, SPAIN](#)

81 Fibrinogen-like protein 2 (FGL2) is a multifaceted immune checkpoint with potential therapeutic application in B-cell non-Hodgkin Lymphomas [Presented by Juan Garcia Valero, FCRB-IDIBAPS, Barcelona & Instituto de Salud Carlos III, Madrid, SPAIN](#)

82 Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype [Presented by Renata Varaljai, University Hospital Essen, GERMANY](#)

83 TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANF clinical study [Presented by Mathieu Virazels, Université Toulouse III & Equipe Labellisée Fondation ARC, Toulouse, FRANCE](#)

84 Optimized tumor deconvolution of major cell types estimates cell proportions associated with cancer patient outcomes and immunotherapy responses Presented by Marie-Claire Wasson, Dalhousie University, Halifax, CANADA

85 Impaired Translation Fidelity Induces Aberrant Peptide Presentation In Melanoma Presented by Chen Weller, Weizmann Institute of Science, Rehovot, ISRAEL

86 Studying the response of TME targeting approaches in a clinically relevant mouse model of mesenchymal glioblastoma Presented by Kieron White, Royal College of Surgeons in Ireland, Dublin, IRELAND

87 Pan-tumor screening of solid tumor responses to NK immune surveillance reveals shared resistance mechanisms Presented by Jennifer Wischhusen, DKFZ & HI-STEM gGmbH, Heidelberg, GERMANY

88 Neo-Scan a flexible MS-immunopeptidomics approach to unbiasedly discover shared neoantigens Presented by Anna Yuste Estevanez, VHIO, Barcelona, SPAIN

89 RNA-sensing pattern-recognition receptors synergize with TLR2 or dectin-1 to trigger high production of IL-12p70 by human dendritic cells Presented by Inger Øynebråten, Oslo University Hospital, Oslo, NORWAY

90 **[POSTER SPOTLIGHT]** The multifaceted role of Ambra1 in melanoma development and response to immunotherapy Presented by Daniela De Zio, Danish Cancer Society Research Center & University of Copenhagen, DENMARK

91 Regulatory T-cells in prostate cancer patients with and without lymph node metastasis Presented by Sabina Davidsson, Örebro University Hospital, Örebro, SWEDEN

92 Modulation of tumour-promoting inflammation in breast cancer by Oncostatin M cytokine: implications in immune suppression Presented by Paloma Petit, Biodonostia Health Research Institute, San Sebastian, SPAIN

EACR on-site team



Chris Iliffe
Conference Officer



Kathryn Wass
Programmes Manager



Claire Sanders
Corporate Engagement
Manager



Samantha Kirk
Communications and
Social Media Coordinator

Conference Dinner

Optional Ticketed Event: Wednesday 10 May, 20:00


The Conference Dinner will take place on the final night of the meeting in the Terraza Mirador at the 5* Hotel Casa Fuster, a short walk from the conference venue. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment.

A cocktail-style dinner will be served, allowing guests to walk around this beautiful setting whilst choosing from a selection of hot and cold plates. Drinks are included in the ticket price.

Venue

Hotel Casa Fuster
Passeig de Gràcia 132,
08008, Barcelona
www.hotelcasafuster.com

It takes only 5-10 minutes to walk from the conference venue to the dinner venue.



Communication.
Collaboration.
Community.

EACR

European Association
for Cancer Research



**NOT A MEMBER
YET? JOIN NOW**

Apply for funding
to develop your
research &
expand
your
horizons



Benefit from
member
registration
rates at EACR
events

Join our
Science Book
Club on
LinkedIn



Build new
connections
with our 'Find a
Collaborator'
tool

Search
the EACR
Member
Network
and message
other members



Share your
perspective: write
for The Cancer
Researcher
magazine

Access
our free
expert
webinars on
research &
careers



Stay informed
with regular
updates on
news, jobs &
conferences

Volunteer for
our Ambassador
Programme or
committees

EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the Association to develop important initiatives.

